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Introduction 
Oligonucleotides have great potential as a new generation of therapeutics (Kole et al., 2012; 
Malhotra et al., 2011). Yet the application of RNA in therapies is hindered by problems with 
pharmaceutical delivery (Guo et al., 2011). Attempts at overcoming the barriers to effective 
systemic and targeted cell-specific delivery of these polyanionic macromolecules have explored 
many formulations, most often using cationic lipids and polymers. The cationic lipids have 
included amphiphilic cationic cyclodextrins (Cryan et al., 2004; O’Mahony et al., 2013; 
O’Mahony et al., 2012; Mendez-Ardoy et al., 2011). Cyclodextrins, as unique monodisperse 
oligosaccharides, lend themselves to chemical modification with multiple charges and polar or 
lipid groups, giving them versatile assembly properties in aqueous conditions (Sallas et al., 
2008). Modifications which are possible while maintaining the useful assembly properties of 
cyclodextrins are many, such as: incorporation of cationic groups to neutralise the anionic 
charges on RNA to promote complexation; and coating of the nanoparticles with ligands by 
molecular inclusion. We have used amphiphilic cationic cyclodextrins for successful delivery of 
siRNA to neuronal cells (O’Mahony et al., 2012; O’Mahony et al., 2012; Godinho et al., 2014; 
Gooding et al., 2015), to prostate cancer cells (Evans et al., 2015), and in a scaffold-based 3D 
prostate cancer bone metastasis model (Fitzgerald et al., 2015). These cyclodextrins have also 
shown successful siRNA delivery and inhibition in vivo in an animal model of Huntington’s 
disease and a xenograft model of prostate cancer (Godinho et al., 2013; Guo et al., 2012). 
Molecular inclusion of adamantyl groups has been employed to coat nanoparticulate 
formulations with the anisamide targeting ligands of adamantly-PEG-anisamide (Fitzgerald et 
al., 2016).  
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Besides complexation with cationic lipids and polymers, chemical conjugation of siRNAs to 
active ligands has also shown promise in facilitating delivery (Gooding et al., 2016). This may, 
for example, involve conjugating siRNAs to small molecules such as peptides that can penetrate 
cellular membranes (Rozema et al., 2007) or to lipophiles such as cholesterol (Wong et al., 
2012). Other studies have shown that conjugation of PEG molecules to siRNA can lead to 
increased stability and gene knockdown efficiency (Gunasekaran et al., 2011; Gaziova et al., 
2014; Shokrzadeh et al., 2014).   
Now we have conjugated β-cyclodextrin (CD) to the sense strand of siRNAs using both a 
bioreducible (disulfide) and a non-reducible (sulfanyl) linker, and have assessed the resulting 
CD-siRNA conjugates for gene knockdown efficiency in cancer cell lines. We reasoned that if 
this major modification to siRNA did not adversely affect its gene knockdown effectiveness, 
then the siRNA thus conjugated could be endowed with assembly properties by the conjugation 
with modified functionalised cyclodextrin which would afford new ways of formulation and 
delivery. Initially in this study siRNA conjugated to simple beta cyclodextrin was delivered to 
cancer cell lines using two different approaches: 1) simple complexation with polycationic lipids, 
Lipofectamine 2000 or a cationic amphiphilic cyclodextrin and, 2) by formulating inclusion 
complexes of adamantyl-PEG-RVG peptide and adamantyl-PEG-dianisamide with the CD-RNA 
conjugates, followed by charge neutralisation with chitosan polycationic polymer. The 
adamantyl RVG- and dianisamide-targeted derivatives were directed at the acetyl choline 
receptors on human brain cancer cells (U87) and sigma receptors on prostate cancer cells (PC3 
and DU145), respectively. In all cases the ability of the CD-siRNA conjugate to retain gene 
silencing activity was assessed. 
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Materials and Methods 
Materials 
Two thiol-modified siRNAs with sequences against luciferase gene and PLK1 gene were 
obtained from Gene Link (NY, USA). The siRNA targeted against luciferase gene had the 
sequence: sense strand, 5’- GAA GUG CUC GUC CUC GUC CCC C dT d  – (Thiol-M C6-D) 
3’ MW 7,979 Da; antisense strand, 5’ - GGG GGA CGA GGA CGA GCA CUU C dT dT  – 3’ 
MW 7,514 Da. The siRNA targeted against PLK1 had the sequence: sense strand, 5’-AGA 
mUCA CCC mUCC UmUA AAmU AUU dT dT – (Thiol-M C6-D) 3’, antisense strand, 5’-
UAU UUA AmGG AGG GUG AmUC UUU-3’, with a total molecular weight of 13,558 Da. 
The PLK1 siRNA had 2’-O-methyl “m” modifications on its nucleotides to protect it from serum 
nucleases.    
 
Synthesis of β-cyclodextrin-RNA conjugates (Scheme) 
All chemicals were purchased from Aldrich and were used without further purification unless 
otherwise noted. Triphenylphosphine was recrystallised from ethanol and dried under high 
vacuum for 6 hours at 50°C before use. β-cyclodextrin was dried for 12 hours at 100°C under 
high vacuum. DMF was purchased in Sureseal bottles over molecular sieves and stored under 
nitrogen.  
Chromatography: Thin-layer chromatography was performed on aluminium-backed plates of 
Merck Silica Kieselgel 60 F254. These were developed by dipping the plates in a 5% sulfuric acid 
in ethanol solution and heating with a heat gun; or in caesium sulfate stain (21 g (NH4)6Mo7O24, 
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1 g Ce(SO4)2, 1 L H2O, 31 mL conc. H2SO4) followed by charring; or in a tank containing iodine 
mixed with sand. Flash chromatography was carried out on Merck Kieselgel 60 0.04-0.063 mm.  
NMR Spectroscopy: 
1
H NMR spectra were recorded using Varian 300, 400 and 500 MHz 
spectrometers at 25°C unless otherwise stated. 
13
C NMR spectra were recorded on Varian 75, 
100 and 125 MHz spectrometers at 25°C unless stated otherwise.  
 
Mass Spectrometry: MALDI-TOF analysis was performed on a Perseptive (Framingham, Mass.) 
Voyager STR instrument equipped with delayed extraction technology. Ions were formed by a 
pulsed UV laser beam (nitrogen laser, 337 nm) and accelerated through 24 kV. Samples were 
diluted in CHCl3 and mixed 1:1 v/v with the matrix solution obtained by dissolving 2,5-
dihydroxybenzoic acid (DHB) in CH3OH-0.1% trifluoroacetic acid-CH3CN (1:1:1 by volume) at 
a concentration of 30 mg/mL. A sample (1mL) of this mixture was deposited onto a stainless 
steel 100-sample MALDI plate and allowed to dry at room temperature (RT) before running the 
spectra in the positive polarity. 
 
Synthesis of 6-Deoxy-6-(3’-(N-maleimido)-propionamido)-β-cyclodextrin (2) 
6-Amino-6-deoxy-β-cyclodextrin (1) was synthesized according to a previously published 
method (Tang et al., 2008). Compound 1 (115 mg, 0.10 mmol) was dissolved in deionised water 
(6 mL) and 3-(N-maleimido)-propionic acid N-hydroxysuccinimide ester (54 mg, 0.20 mg) was 
added in DMF (1.4 mL).  The solution was stirred for 3 h at RT, then the product (2) was 
precipitated with acetone and washed several times with acetone (yield 101 mg, 79%). 
1
H-NMR (400 MHz, DMSO-d6): δ 6.97 (s, 2H), 5.73 (m, 14H), 4.82 (s, 7H), 4.67 (m, 7H), 3.82-
3.47 (m, 30 H). 
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13
C-NMR (101 MHz, DMSO-d6): δ 171.1, 134.9, 102.4, 82.0, 73.5, 72.9, 72.5, 60.4. 
ESI-MS (m/z): 1307.66 [M + Na]+. 
Molecular weight: 1285.11894 Da; molecular formula: C49H76N2O37 
 
Synthesis of 6-deoxy-6-(3'-(2’’-pyridyldithio)-propionamido)-β-cyclodextrin (4) 
6-Amino-6-deoxy-β-cyclodextrin (1) (45 mg, 0.04 mmol) was dissolved in deionised water (4 
mL) and 3-(2’-pyridyldithio) propionic acid N-hydroxysuccinimide ester (25 mg, 0.08 mg) was 
added in DMF (1.2 mL).  The mixture was stirred for 3 h at RT and the product (4) was 
precipitated with acetone and washed several times with acetone (46 mg, 86%).  
1
H NMR (400 MHz, DMSO-d6) δ 8.43 (d, J = 4.7 Hz, 1H), 7.91 – 7.64 (m, 2H), 7.33 – 7.11 (m, 
1H), 6.00 – 5.48 (m, 6H), 4.96 – 4.67 (m, 3H), 4.43 (s, 3H), 3.87 – 3.43 (m, 10H), 3.44 – 3.08 
(m, 25H, overlap with D2O). 
13
C NMR (101 MHz, DMSO-d6) δ 170.49, 159.64, 149.98, 138.25, 119.53, 102.37, 73.43, 72.85, 
72.46, 60.34, 34.50. 
ESI-MS (m/z): 1328.66 [M - H]- 
Molecular weight: 1331.27672 Da; molecular formula: C50H78N2O35S2 
 
Complete reduction of thiol-modified siRNA 
Thiol-modified luciferase siRNA, and thiol-modified PLK1 siRNA, was fully reduced according 
to the manufacturer’s protocol (Gene Link, USA). Briefly, 1 mL of 3% TCEP (tris(2-
carboxyethyl)phosphine) solution was freshly prepared by adding 30 µL of TCEP to 970 µL of 
sterile RNAse-free water. From this solution, 400µL was added to the lyophilized thiolated 
siRNA. The solution was left at RT for 1 hr, then 50 µL of 3M sodium acetate solution at pH 5.2 
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was added before again vortexing. Absolute ethanol (1.5 mL) was added to the solution which 
was vortexed briefly and stored at -80°C for 20 minutes. The sample was centrifuged at 13,680 g 
for 10 minutes, the supernatant was decanted and the pellet air dried. The pellet was dissolved in 
200 µL of sterile phosphate-buffered saline (PBS), pH 7.2. Total concentration of the siRNA in 
200 µL was determined by measuring absorbance at 260 nm, using a Nanodrop 
spectrophotometer. 
 
Conjugation of siRNA with 6-Deoxy-6-(3’-(N-maleimido)-propionamido)-β-cyclodextrin (3) 
A 100-molar excess of 6-deoxy-6-(3’-(N-maleimido)-propionamido)-β-cyclodextrin (2) in 50 µl 
of RNAse-free water was added to a solution of a fully reduced thiol-modified siRNA (luciferase 
siRNA or PLK1 siRNA) (100 µL in PBS, pH 7.2). The reaction solution was vortexed gently and 
incubated at RT overnight to obtain the CDmal-siRNA conjugate (3). Excess of the cyclodextrin 
was removed with Amicon centrifugal filters (M.W. 3000) (Millipore, Ireland) at 2,370 g and the 
solution was reconstituted with 100 µL of RNAse-free water. The concentration of CDmal-
siRNA conjugate (3) was determined by measuring absorbance at 260 nm using a Nanodrop 
spectrophotometer. 
 
Conjugation of siRNA with 6-deoxy-6-(3'-(2’’-pyridyldithio)-propionamido)-β-cyclodextrin (5)  
A 100-molar excess of 6-deoxy-6-(3’-(2’’-pyridylthio)-propionamido)-β-cyclodextrin (4) in 100 
µl of DMSO was added to a solution of fully reduced thiol-modified siRNA (100 µL in PBS 
buffer, pH 7.2). The pH was adjusted to 4-5 with 1M HCl and 100 mM sodium acetate. The 
reaction mixture was gently vortexed and incubated at 35°C overnight to obtain the CDSS-
siRNA conjugate (5). Excess of cyclodextrin was removed by using Amicon centrifugal columns 
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(M.W. 3000) (Millipore, Ireland) at 2,370 g, and the solution was reconstituted with 100 µL of 
RNAse-free water. CDSS-siRNA concentration was determined by measuring absorbance at 260 
nm using a Nanodrop spectrophotometer. 
Gel retardation assay of CD-siRNA conjugates 
Agarose (1% w/v) (Sigma, MO, USA) solution was prepared with 1X Tris borate EDTA (TBE) 
buffer to which 6 µL of SafeView™ (NBS Biologicals Ltd, England) was added to visualize 
siRNA bands under UV light. The unconjugated and conjugated siRNA (36 µL) were each 
mixed with 10X Blue Juice gel loading buffer (4 µL) (Invitrogen, Carlsbad, California). 
Electrophoresis was carried out at 90 V for 45 minutes in TBE buffer. The siRNA bands were 
visualized by UV using DNR Bioimaging Systems MiniBis Pro and Gel capture US B2 software.  
 
Electron-spray ionisation (ESI) mass spectroscopy of CD-siRNA conjugates 
The samples for ESI were prepared at a concentration of 40-50 µM in 0.1M TEAA 
(triethanolamine acetate) buffer, pH 7. A C18 column was used with the following mobile phase: 
solvent A, 15 mM TEA with 400 mM HFIP (hexafluoro-2-propanol) (pH 7.9), measured by 
weight; solvent B, 50% solvent A with 50% methanol (v/v).  
 
Cell culture 
The human prostate cancer cells, DU145, were kindly donated by the Conway Research Institute, 
(University College Dublin, Dublin, Ireland). PC3 and PC3-Luc (over-expressing luciferase 
gene) were procured from European Collection of Cell Cultures (ECACC), UK and were grown 
in RPMI 1640 cell culture medium. Human glioblastoma cell line (U87) was a kind gift from Dr. 
Paul Young (University College Cork); cells were grown in DMEM. All culture media were 
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supplemented with 10% foetal bovine serum (FBS), 2 mM L-Glutamine, 50 units/ml penicillin 
and 50 µg/ml streptomycin. For passaging, 0.05% trypsin-EDTA (GIBCO, UK) was used. The 
cells were maintained in a humidified chamber at 37 °C with 5% CO2. 
Cellular delivery of CD-siRNA conjugates complexed with Lipofectamine 2000 
Cellular delivery of luciferase CD-siRNA conjugates was performed using Lipofectamine 2000 
(Sigma, USA): 50 nM of unconjugated or conjugated siRNA was delivered using Lf2000 with 
final vector:siRNA ratio 1µL Lf2000 : 20 pmol siRNA, as recommended by the supplier. 10,000 
PC3-Luc cells/well were seeded in a 96-well white-opaque plate and transfection was carried out 
after 24 hours of seeding. The cells were incubated with the treatment samples for 4 hours, after 
which the medium was replaced with complete growth medium. The percentage of luciferase 
gene knockdown (protein suppression) was analyzed at 48 hours by measuring the luminescence 
intensity using a multiplate reader (Perkin Elmer – Wallac Victor 2TM 1420 multilabel counter). 
 
 
Cellular delivery of CD-siRNA conjugates complexed with heptakis[2-O-(N-(3′′-aminopropyl)-
1′H-triazole-4′-yl-methyl)-6-dodecylthio]-β-cyclodextrin (a cationic amphiphilic cyclodextrin) 
The cationic amphiphilic cyclodextrin was synthesized as previously described (O’Mahony et 
al., 2012). CD-siRNA nanocomplexes with cationic amphiphilic cyclodextrin were prepared 
following a published protocol (O’Mahony et al., 2012). Briefly, the cationic amphiphilic 
cyclodextrin was dissolved in chloroform (1mg/ml). The chloroform was evaporated under 
nitrogen gas to leave a thin layer of cyclodextrin, which was rehydrated with ddH2O, at a final 
concentration of 1µg/µl. The aqueous solution was sonicated for an hour at RT before forming 
nanocomplexes with CD-siRNA conjugates. The cationic amphiphilic cyclodextrin 
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nanocomplexes with CD-siRNA conjugates were formed at mass ratio (MR) 20 (Singh et al., 
2010). Specifically, 60µg of the cationic amphiphilic cyclodextrin in 800µl of ddH2O, and 3µg 
of either unconjugated or conjugated CD-siRNA (CDmal-siRNA and CDSS-siRNA) each in 
200µl of ddH2O were separately dissolved. The CD-siRNA conjugate (200µl) was then added 
dropwise (2-3 drops each time) to the cationic amphiphilic cyclodextrin solution (800µl) and 
vortexed at a mild speed for 10-15 seconds, to give a final volume of 1 ml. he nanocomplexes 
were kept at RT for 30 mins for stabilisation. 
 
PC-3 cells (100,000 cells/well) were seeded in a 24-well plate. CD-siRNA (PLK1) conjugates 
(50 nM) were delivered using the cationic amphiphilic cyclodextrin vector in serum-free and 
antibiotic-free medium. The medium was replaced with fresh complete growth medium (10% 
FBS) after 24 hours transfection. The percentage gene (PLK1) knockdown was determined at 48 
hours by performing RNA extraction and qRT PCR.  
 
Preparation of targeted CD-siRNA formulations with adamantyl-PEG-ligand and chitosan, 
and cellular delivery 
Cell-targeted inclusion complexes of CD-siRNA conjugates were prepared using adamantyl-
PEG500-RVG and adamantyl-PEG5000-dianisamide (AA2), and untargeted complexes using 
adamantane-PEG500 and adamantane-PEG500, respectively, at molar ratio 1:1. RVG ligand 
targeted acetylcholine receptors on U87 (human brain cancer cells) and AA2 targeted sigma 1 
receptors on DU145 (human prostate cancer cells). Equimolar ratios of targeted and untargeted 
adamantyl derivatives were separately added to the CD-siRNA conjugates and mixed in a 
thermomixer at 900 rpm for 30 mins at RT. The inclusion complexes were then added drop-wise 
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to a solution of chitosan polymer (0.5 mg/mL, in 1% acetic acid, pH5) to form nanoparticles at 
MR 1 and 10. (Conditions for this formulation with chitosan had previously been optimised: 
Supplementary information). The mixture was vortexed mildly for 10-15 seconds, then left at 
RT for 30 mins. Concentration of CDmal-siRNA conjugate used was 100 nM. The nanoparticles 
prepared as above were incubated with U87 cells (25,000 cells/well in 24 well plate) and DU145 
cells (50,000 cells/well in 24 well plate) for 24 hrs and gene knockdown was analyzed at 48 hrs. 
For competitive inhibition assay in U87 cells (25,000 cells/well in 24 well plate), inclusion 
complex with the adamantyl-PEG500-RVG (targeted) formulation was formed and complexed 
with chitosan polymer at MR 1 and 10. For DU145 cells (50,000 cells/well in 24 well plate), 
inclusion complex with the adamantyl-PEG5000-AA2 (targeted) formulation was formed and 
complexed with chitosan polymer at MR 1 and 10. The cells were either treated or untreated with 
the 30µM of RVG peptide (U87 cells) for 30 mins and 100µM of adamantly-PEG5000-AA2 for 
1 hr (DU145 cells), followed by treatment with their respective targeted formulations for 4 hrs. 
The PLK 1 gene knockdown analysis was performed at 24 hrs.    
 
Determination of gene knockdown using quantitative real-time PCR 
Cells were lysed and RNA was extracted after 48 hours transfection using GenElute
TM 
Mammalian Total RNA Miniprep Kit (Sigma) as per manufacturer’s instructions. Concentration 
of the total RNA was quantified using a NanoDrop ND-1000 UV-vis Spectrophotometer and 
complementary DNA (cDNA) was generated using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Gene expression was assessed by real-time qPCR using 
the Applied Biosystem’s Real Time PCR System (Model 7300). Cycling conditions were as 
follows: 10 min (min) at 95 °C, 40 cycles [of 15 sec at 95 °C; 1 min at 60 °C]. Assays were 
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performed using appropriate primer sets for PLK1 (catalogue number Hs00153444_m1) and β-
actin (catalogue number Hs01060665_g1) (Taqman®, Applied Biosystems). The quantitative 
level of each PLK1 mRNA was measured as a fluorescent signal corrected according to the 
signal for β-actin mRNA. The 2-delta Ct method was used to quantify the relative changes in 
mRNA. 
 
Statistical Analysis 
Statistical analysis was carried out using Graphpad Prism 5 software (CA, USA). Statistical 
comparisons were carried out using One-way analysis of variance (ANOVA) followed by 
Tuckey’s Post Hoc test and unpaired two-tailed student t-test. Statistical significance was set at P 
<0.05, P<0.01 and P values < 0.001 were considered highly significant. 
 
Results and Discussion 
Synthesis and characterization of CD-siRNA conjugates  
CD-siRNA conjugates were prepared using biologically non-cleavable (sulfanyl) and cleavable 
(reducible disulphide) linkers between the cyclodextrin and siRNA. To obtain a non-cleavable 
link, 6-amino-β-cyclodextrin was reacted with 3-(N-maleimido)-propionic acid N-
hydroxysuccinimide ester according to the synthetic Scheme to obtain product 2 in 79% yield. 
To obtain a cleavable link, 6-amino-β-cyclodextrin was reacted with 3-(2’-pyridyldithio) 
propionic acid N-hydroxysuccinimide ester according to the Scheme to obtain product 4 in 86% 
yield. The siRNAs used for conjugation (luciferase and PLK1) had thiol modification on the 3’ 
end of the sense strand and were fully reduced according to the manufacturer’s protocol, prior to 
conjugation. Reacting the reduced siRNAs with the activated cyclodextrins 2 and 4 gave the 
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conjugates CDmal-siRNA 3 and CDSS-siRNA 5, where each conjugate had either luciferase or 
PLK1 siRNA. Successful conjugation was confirmed by gel retardation assay (Figure 1), which 
show band shifts relative to the unconjugated siRNA. Conjugation was further confirmed by 
mass spectroscopic (ESI) analysis (Figure 2, Table1). The molecular weights of sense and 
antisense strands of luciferase siRNA as stated by the supplier (Gene Link, USA) were 7979 Da 
and 7514 Da, respectively. ESI showed successful conjugation of luciferase siRNA (sense 
strand) with CD-mal (MW 1285.11 Da) (Figure 2B) and CD-SS (MW 1331.27 Da) (Figure 
2C), resulting in increased molecular weights of 9261.63 Da and 9325.54 Da.  
 
Cellular delivery of CD-siRNA conjugates using polycationic lipids Lipofectamine 2000 
and heptakis[2-O-(N-(3′′-aminopropyl)-1′H-triazole-4′-yl-methyl)-6-dodecylthio]-β-
cyclodextrin 
Figure 3 shows the reduction in luminescence intensity of PC3-Luc cells (overexpressing 
luciferase protein) on treatment with luciferase siRNA or its cyclodextrin conjugates, CDmal-
siRNA and CDSS-siRNA, mediated by Lf2000 for 4 hrs. Suppression of luciferin protein in 
PC3-Luc cells by the conjugated siRNA was found to be comparable to that for the unconjugated 
siRNA (P>0.05). This confirmed that conjugating cyclodextrin at the 3’end of siRNA does not 
hinder the silencing ability of siRNA.  
 
A similar mode of delivery used the less cytotoxic cyclodextrin vector heptakis[2-O-(N-(3′′-
aminopropyl)-1′H-triazole-4′-yl-methyl)-6-dodecylthio]-β-cyclodextrin. Mass ratio MR 20 
(cyclodextrin:siRNA) is known to be optimal (O’Mahony et al., 2012) and non-toxic to cells 
over 24 hours (Evans et al., 2015). Figure 4 shows that PLK1 gene knockdown by CD-siRNA 
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conjugates, quantified by qRT-PCR, was comparable to that of the unconjugated siRNA (67% 
expression) (P<0.05). The siRNA conjugated through a cleavable (disulfide) linker showed 
greater knockdown (57% expression) compared to the siRNA conjugated through a non-
cleavable (maleimide) linker (73% expression) (P<0.001). This result is in accordance with other 
studies (Singh et al., 2010). More importantly, siRNA conjugation with cyclodextrin does not 
cause the silencing inhibition observed, for example, with conjugated PEG molecules of large 
molecular weight (Jung et al., 2010; Iversen et al., 2013).  
 
Cellular delivery of CD-siRNA conjugates using a targeted nanoparticle formulation 
Besides delivery by polycationic lipids, which demonstrated the ability of the CD-siRNA 
conjugates to produce knockdown, we incorporated the conjugates into nanoparticulate 
formulations to demonstrate the special assembly properties conferred on the RNA by such 
conjugation. As outlined in Figure 5A, the molecular inclusion properties of the cyclodextrin 
moiety was first used to incorporate an adamantyl-conjugated targeting ligand (RVG or 
dianisamide), and the resulting polyanionic RNA assembly was charge-neutralised with 
(polycationic) chitosan to create ligand-directed nanoparticles. An isothermal calorimetry (ITC) 
analysis for CD and adamantyl-PEG compounds has shown that PEGylation of adamantane does 
not seriously inhibit the formation of inclusion complexes with cyclodextrins (Fitzgerald et al., 
2016). Following the formation of inclusion complexes with the CD-siRNA conjugates, the 
complexes were mixed with chitosan polymer at MR 1 and 10. The use of chitosan polymer was 
first optimized with unmodified, non-conjugated siRNA (FAM-labelled scrambled) 
(Supplementary information). Chitosan was chosen as a charge-neutralising polymer due to its 
low toxicity, biodegradability and “proton sponge” effect that aids endosomal release of the 
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nanoparticle (Malhotra et al., 2009). This optimization ensured that cellular uptake of 
nanoparticles is specifically through the targeting ligands on their surface and not through the 
positive charge of excess chitosan.  
Figure 5A illustrates the steps to form targeted nanoparticles using CD-siRNA conjugates.  The 
optimization (Supplementary information) confirmed formation of nanoparticles with near 
neutral surface charge and size ~100 nm at chitosan:siRNA MR of 1 and 10. The purpose of 
selecting nanoparticles at MR 1 and 10 was to compare the ability of the nanocomplexes to 
deliver the therapeutic via receptor-mediated delivery, thereby eliminating non-specific 
adsorptive endocytosis. Also, it is known from literature that loose complex with less 
electrostatic interaction fail to deliver therapeutics as efficiently as the compactly complexed 
nanoparticles (Park et al., 2013). The reason is the lack of target specificity, which leads to a lack 
of endocytosis by the cell membrane. Thus, we tested complexes formed at MR 1 (loose 
nanoparticles) and MR 10 (compact nanoparticles), which had just the optimal amount of 
cationic chitosan polymer necessary to compact the siRNA while preventing inhibition of the 
ligand-guided, receptor-mediated delivery. Figure 5B and 5C represent relative PLK1 
expression in U87 and DU145 cells analyzed using qRT-PCR. Gene knockdown of 30 - 40 % 
(P<0.0001) was obtained at MR1 and 60 - 70% (P<0.0001) at MR10 in U87 cells, with the 
RVG-targeted formulation being especially significant (P<0.05), when compared with the 
untargeted formulation or the conjugate alone. A similar trend was obtained in DU145 cells with 
the anisamide targeting ligand where gene knockdown levels of: 40 - 50% at MR1 (P<0.0001) 
and 75% at MR 10 (P<0.0001) were detected. At MR 1, however the difference was not 
statistically significant.  
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To further validate the receptor-mediated uptake of the targeted nano-formulation, a competitive 
inhibition assay was performed. As shown in Figure 5D and 5E, while the effect detectable with 
MR1 was not significant, pre-treatment with the ligand significantly lowered the knockdown 
levels for chitosan formulations at MR10. These results demonstrate that ligand targeting can be 
successfully achieved with these formulations by exploiting the inclusion complex formation 
abilities retained in the CD-siRNA conjugates. 
In summary, this is the first example of formation of CD-siRNA conjugates. It has been shown 
that cyclodextrin can be covalently attached to the sense strand of siRNA without adversely 
affecting its knockdown ability. Such conjugation can also involve the RNA in the versatile self-
assembly properties of the cyclodextrin thus providing new opportunities to develop 
unconventional formulations for therapeutic oligonucleotides.  
 
Conclusion 
Cyclodextrin has been successfully conjugated at its 6-position, via disulfide and sulfanyl links, 
to the sense strands of siRNAs at the 3’-position. Retention of the gene knockdown activity of 
the RNAs, directed at cancer cells that over-express either luciferase gene or PLK1 gene, was 
assessed by delivery of the CD-RNA conjugates using two polycationic lipids: Lipofectamine 
2000 and a polycationic amphiphilic cyclodextrin. Knockdown activity has been found to be 
comparable to that of the unconjugated RNAs as delivered by the same vectors, demonstrating 
that the chosen modes of conjugation to the cyclodextrin do not adversely affect its functioning 
as an enzyme substrate in the interference pathway. In addition, the disulphide-linked conjugates 
demonstrated a significantly higher level of knockdown compared to the sulfanyl-linked 
conjugates, probably due to disulfide biolability.  
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Following confirmation of the silencing activity of CD-siRNA conjugates, an example of 
performance of the cyclodextrin moiety in enabling a new mode of formulating RNA was 
assessed. This involved formation of a molecular inclusion complex by the conjugated 
cyclodextrin with adamantyl-PEG-ligand to exploit ligand targeting, and charge neutralisation by 
chitosan. Superior knockdown was obtained with these targeted formulations, demonstrating that 
CD-siRNA conjugates can enable formation of targeted charge-neutral formulations for receptor-
mediated endocytosis. Further studies will involve evaluation of RNA conjugates with modified 
functionalised cyclodextrins.  
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Figures: 
 
 
Scheme: Synthesis of CD-siRNA conjugates from mono-6-amino-6-deoxy-β-cyclodextrin (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
25 
 
 
 
 
 
(A)            (B)  
 
 
(C) 
 
Figure 1: Gel retardation assays of siRNAs and their cyclodextrin conjugates: (a) CDmal-siRNA 
(luciferase); (b) CDSS-siRNA (luciferase); (c) CDmal-siRNA and CDSS-siRNA (PLK1). 
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Figure 2: ESI measurement of (A) unconjugated sense strand of Luciferase siRNA (M.W. 
7725.54), (B) conjugated sense strand of siRNA with CDmal (M.W. 9261.63) and (C) 
conjugated sense strand of siRNA with CDSS (9325.54).    
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Figure 3: Reduction in luminescence intensity of PC3-Luc (luciferase) cells on treatment with 
CD-siRNA (luciferase) conjugates delivered by Lipofectamine 2000: (A) CDmal-siRNA, (B) 
CDSS-siRNA. The graph shows a representative result of (n = 6) mean ± S.D. ***P < 0.001 was 
considered highly significant based on Tuckey’s posthoc analysis. 
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Figure 4: Gene knockdown in PC3 cells with CD-siRNA (PLK1) conjugates (50 nM) delivered 
by cationic amphiphilic cyclodextrin at MR 20. The graph shows a representative result of (n = 
4) mean ± S.D. **P < 0.01 and ***P < 0.001 were considered highly significant based on 
Tuckey’s posthoc analysis. 
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Figure 5: (A) Impression of complexation of CD-siRNA with adamantyl-PEG-ligands and chitosan to form targeted 
nanoparticles.  Gene knockdown in (B) U87 and (C) DU145 cells by CDmal-siRNA (PLK1) conjugate (100 nM), 
complexed with adamantyl-PEG (Ad-PEG500/5000) or –PEG500-RVG or –PEG5000-AA2, and chitosan at MR 
(chitosan:CD-siRNA conjugate) 1 and 10. Competitive inhibition assay in (D) U87 cells and (E) DU145 cells with 
CDmal-siRNA (PLK1) conjugate (100 nM), complexed with adamantyl-PEG500-RVG and adamantyl-PEG5000-AA2, 
respectively and chitosan at MR (chitosan:CD-siRNA conjugate) 1 and 10. The graph shows a representative result 
of (n = 4) mean ± S.D. Graphs (B) and (C) were analyzed by One-way Anova where *P < 0.05 and ***P < 0.001 
were considered highly significant based on Tuckey’s posthoc analysis. Graphs (D) and (E) were analysed by 
unpaired, two-tailed student t-test where *P < 0.05 and **P<0.01 were considered significant. 
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Sample Calculated mass of  
sense strand (Da) 
Theoretical mass of  
sense strand (Da) 
Luciferase siRNA 7725.54 7979 
CD-mal-siRNA 9261.63 9264.11 
CD-SH-siRNA 9325.54 9310.27 
 
Table 1: ESI mass of CDmal (M.W. 1285.11 Da) and CDSS (M.W. 1331.27 Da), conjugated 
with the sense strand of (Luciferase) siRNA.  
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